Incruse Ellipta is a newly approved inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
It was approved by the FDA on April 30, 2014, and will be available by the end of 2014 according to the manufacturer.
What is COPD?
COPD is a disease of the lungs which makes it difficult to breathe. COPD is a disease that unfortunately gets worse over time. There are 2 forms of COPD: chronic bronchitis and emphysema.
Chronic bronchitis is the inflammation and swelling of the airways within your lungs. This causes the lining of the airways to thicken which in turn causes mucus to get stuck, making it hard to breathe.
Emphysema is when the air sacs within the lungs become damaged which decreases oxygen to your lungs making it hard to breathe.
Some common signs and symptoms of COPD include constant coughing, shortness of breath, trouble breathing, wheezing, excess mucus, fatigue, and respiratory infections.
What type of medication is Incruse Ellipta and how does it work?
Incruse Ellipta is considered an anticholinergic or long-acting muscarinic antagonist (LAMA). It works by relaxing and widening the airways within the lungs, which leads to easier breathing.
Can you use Incruse Ellipta on an as-needed basis?
NO. This is a once-daily maintenance medication that will need to be used whether you think you need it or not.
What are the most common side effects of Incruse Ellipta?
The most common side effects of Incruse Ellipta include: nasopharyngitis (AKA the common cold), upper respiratory tract infection, cough, and joint pain.
Are there any other medications similar to Incruse Ellipta for COPD?
Yes. Spiriva Handihaler and Tudorza Pressair are similar to Incruse Ellipta, and also used for long-term maintenance treatment of COPD. Unfortunately, there are no generic options for any of these inhalers yet; they are all brand-name only.
Where can I find more information on Incruse Ellipta?